new
type
coronaviru
identifi
caus
agent
underli
middl
east
respiratori
syndrom
mer
mer
coronaviru
merscov
spread
middl
east
case
origin
middl
east
also
occur
european
union
usa
eight
hundr
thirtyseven
case
merscov
infect
confirm
date
includ
death
merscov
infect
dromedari
camel
popul
middl
east
high
rate
repres
immedi
sourc
human
infect
merscov
spike
protein
characterist
structur
compon
viral
envelop
consid
key
target
vaccin
coronaviru
infect
initi
attempt
develop
merscov
vaccin
ultim
target
dromedari
camel
construct
two
recombin
adenovir
vector
encod
fulllength
merscov
protein
extracellular
domain
protein
balbc
mice
immun
candid
vaccin
intramuscularli
boost
three
week
later
intranas
vaccin
anim
antibodi
respons
spike
protein
neutral
merscov
vitro
result
show
adenoviralbas
vaccin
induc
merscovspecif
immun
respons
mice
hold
promis
develop
prevent
vaccin
target
anim
reservoir
might
effect
measur
elimin
transmiss
merscov
human
new
type
coronaviru
identifi
caus
agent
underli
respiratori
syndrom
recent
emerg
middl
east
coronaviru
studi
group
intern
committe
taxonomi
virus
propos
new
name
novel
betacoronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
sever
middl
eastern
countri
affect
emerg
merscov
epidem
includ
jordan
qatar
oman
saudi
arabia
unit
arab
emir
tunisia
report
three
confirm
case
human
infect
franc
itali
germani
unit
kingdom
greec
netherland
usa
also
report
case
directli
indirectli
connect
middl
east
eight
hundr
thirtyseven
case
merscov
infect
confirm
date
includ
death
rapid
accumul
inform
sequenc
merscov
genom
structur
protein
open
excit
possibl
develop
candid
vaccin
other
recent
provid
evid
dromedari
camel
reservoir
merscov
viru
merscov
spike
proteinbind
antibodi
virusneutr
antibodi
report
dromedari
camel
differ
region
includ
qatar
saudi
arabia
oman
egypt
moreov
merscov
dromedari
camel
farm
qatar
link
two
virolog
confirm
human
case
infect
octob
one
five
human
case
report
caus
exposur
anim
full
merscov
genom
isol
qatari
dromedari
camel
highli
similar
human
englandqatar
viru
isol
effici
http
elsevi
ltd
right
reserv
replic
human
cell
use
human
entri
receptor
provid
evid
zoonot
potenti
dromedari
merscov
although
conclud
whether
peopl
infect
camel
vice
versa
yet
anoth
sourc
respons
increas
evid
indic
camel
repres
import
link
human
infect
merscov
intens
vaccin
control
riskreduct
target
dromedari
camel
might
effect
elimin
viru
human
popul
coronaviru
spike
protein
class
fusion
protein
cellular
entri
viru
demonstr
mediat
protein
receptor
bind
domain
rbd
ntermin
subunit
fusion
peptid
ctermin
subunit
betacoronavirus
protein
shown
main
antigen
compon
respons
induc
high
titer
neutral
antibodi
andor
protect
immun
infect
patient
recov
sar
respons
level
correl
well
diseas
outcom
protein
therefor
select
import
target
vaccin
develop
recent
work
show
modifi
vaccinia
viru
ankara
express
protein
merscov
elicit
high
titer
sspecif
neutral
antibodi
mice
adenoviru
vector
candid
vaccin
induc
potent
protect
immun
respons
sever
pathogen
human
varieti
anim
although
trial
candid
prevent
vaccin
show
lack
efficaci
high
preval
preexist
immun
may
major
limit
human
replicationdefect
adenoviru
vaccin
among
attract
vector
veterinari
vaccin
develop
given
rel
speed
low
cost
develop
product
adenovirus
infect
host
airway
epithelium
replic
mucos
tissu
respiratori
tract
abil
elicit
mucos
immun
respons
adenovirus
could
attract
vector
induc
merscovspecif
immun
dromedari
camel
put
anim
reservoir
interestingli
sera
antibodi
adenoviru
type
detect
dromedari
nigeria
camel
egypt
occurr
adenoviru
type
respiratori
infect
camel
studi
sudan
seropreval
detect
describ
develop
recombin
type
adenovir
vector
express
codonoptim
merss
vaccin
candid
investig
abil
induc
neutral
immun
respons
mice
moreov
demonstr
feasibl
use
human
adenoviru
base
vaccin
dromedari
camel
evalu
infect
presenc
antiadenoviru
antibodi
anim
speci
merss
genbank
gene
codonoptim
optim
express
mammalian
cell
use
upgen
codon
optim
algorithm
synthes
genscript
padmerss
gener
subclon
codonoptim
merss
gene
shuttl
vector
padlox
genbank
salinoti
site
code
sequenc
amino
acid
fulllength
mer
accord
genebank
databas
amplifi
polymeras
chain
reaction
insert
shuttl
vector
fig
subsequ
replicationdefect
human
adenoviru
serotyp
design
gener
loxp
homolog
recombin
purifi
store
describ
previous
detect
merss
protein
express
cell
human
lung
adenocarcinoma
epitheli
cell
line
infect
five
multipl
infect
moi
ad
cell
fix
cold
methanol
h
follow
infect
incub
pool
mous
sera
adenovir
vaccin
wash
cell
incub
horseradish
peroxidasecoupl
antimous
secondari
antibodi
invitrogen
merss
protein
visual
avidinbiotin
complex
solut
vector
bablc
mice
inocul
intramuscularli
im
viral
particl
vp
ad
control
respect
three
week
primari
immun
mice
boost
intranas
dose
respect
immunogen
immun
studi
protocol
approv
univers
pittsburgh
institut
anim
care
use
committe
follow
three
week
prime
immun
pool
sera
obtain
mice
screen
merssspecif
antibodi
use
fluorescenceactiv
cell
sorter
fac
analysi
human
embryon
kidney
hek
cell
transfect
either
padmerss
pad
control
use
lipofectamin
invitrogen
h
c
cell
harvest
trypsin
wash
phosphat
buffer
salin
pb
stain
mous
antiserum
ad
follow
peconjug
antimous
secondari
antibodi
jackson
immuno
research
data
acquisit
analysi
perform
use
lsrii
bd
flowjo
tree
star
softwar
sera
anim
collect
everi
week
test
proteinspecif
convent
enzymelink
immunosorb
assay
elisa
briefli
cell
infect
moi
six
hour
infect
cell
wash
three
time
pb
serumfre
media
ad
cell
incub
h
elisa
plate
coat
supernat
cell
infect
overnight
c
carbon
coat
buffer
ph
block
pb
contain
tween
pbst
bovin
serum
albumin
bsa
h
mous
sera
dilut
elisa
pbst
bsa
incub
h
plate
wash
biotinconjug
ebiosci
avidinhorseradish
peroxidas
hrp
pharmingen
ad
well
incub
h
plate
wash
three
time
develop
tetramethylbenzidin
reaction
stop
h
absorb
nm
determin
use
elisa
reader
biotek
instrument
stock
merscov
produc
prepar
sixth
passag
merscov
emc
isol
vero
cell
cell
inocul
viru
dulbecco
modifi
eagl
medium
biowhittak
supplement
serum
uml
penicillin
mgml
streptomycin
mm
glutamin
inocul
cultur
incub
c
co
incub
three
day
inocul
supernat
vero
cell
collect
test
merscov
neutral
activ
sera
deriv
mice
immun
ad
vaccin
mous
sera
obtain
retroorbit
plexu
weekli
six
week
test
abil
neutral
merscov
emc
isol
briefli
viru
pfu
premix
serial
dilut
sera
anim
group
prior
inocul
onto
vero
cell
viral
infect
monitor
occurr
cytopath
effect
h
postinfect
viru
neutral
titer
vnt
determin
highest
serum
dilut
show
full
protect
cytopath
effect
merscov
test
adenoviru
neutral
activ
sera
camel
human
qatar
healthi
individu
procedur
perform
complianc
relev
law
institut
guidelin
briefli
adenoviru
express
green
fluoresc
protein
gfp
pfu
premix
serial
dilut
sera
prior
inocul
onto
cell
viral
infect
monitor
detect
gfpposit
cell
h
vnt
determin
highest
serum
dilut
show
reduct
number
adenovirusinfect
cell
freshli
isol
camel
human
peripher
blood
mononuclear
cell
pbmc
seed
cellsml
plate
incub
h
c
next
cell
infect
vp
complet
medium
incub
h
c
co
adenovirusinfect
cell
examin
enhanc
gfp
express
use
invert
fluoresc
microscop
olympu
percentag
cell
analyz
measur
mean
fluoresc
signal
fac
bd
bioscienc
egfpexpress
cell
monocyt
popul
analyz
gate
use
flowjo
softwar
dromedari
camel
fibroblast
cell
line
dubca
atcc
tm
cell
seed
cellswel
plate
infect
moi
h
infect
flow
cytometri
cell
analyz
use
lsrii
flowjo
softwar
statist
analysi
oneway
analysi
varianc
tukey
test
perform
use
prism
softwar
san
diego
california
usa
result
consid
statist
signific
p
valu
symbol
use
indic
p
valu
respect
delet
human
type
adenovir
vector
use
insert
fulllength
extracellular
domain
codonoptim
merss
open
read
frame
gener
adenovir
vector
fig
detect
mer
protein
express
recombin
adenovir
candid
vaccin
cell
infect
ad
incub
pool
day
sera
admer
control
immun
mice
immunocytochem
analysi
show
express
mer
protein
cell
infect
either
express
detect
mock
ad
cell
set
infect
cell
stain
pool
sera
mice
immun
ad
data
shown
furthermor
cell
transduc
fulllength
merss
show
plaquelik
structur
may
result
syncytium
format
due
mer
full
length
protein
express
solubl
form
mer
protein
detect
intracellularli
presum
secret
show
syncytium
format
fig
mice
develop
merssspecif
antibodi
measur
reactiv
cell
transfect
pad
use
flow
cytometri
specif
antibodi
respons
detect
serum
sampl
control
anim
inocul
ad
preimmun
mous
sera
fig
specif
respons
slightli
higher
mice
immun
mice
immun
vs
posit
cell
data
suggest
adenovir
vaccin
express
merss
abl
induc
sspecif
antibodi
sera
mice
collect
everi
week
boost
vp
control
ad
respect
test
proteinspecif
immunoglobulin
isotyp
indic
respons
respect
elisa
detect
soon
one
week
first
immun
induct
merssspecif
antibodi
compar
immun
group
shown
fig
significantli
differ
respons
observ
sera
mice
vaccin
p
week
p
week
compar
sera
mice
vaccin
ad
fact
level
sera
mice
vaccin
show
less
signific
differ
p
week
p
week
contrast
highli
signific
differ
respons
observ
sera
mice
vaccin
p
week
fig
interestingli
merss
induc
earlier
respons
p
vs
signific
week
titer
significantli
higher
week
p
week
merss
specif
serum
antibodi
respons
could
detect
within
seven
week
period
mice
immun
control
adenoviru
ad
data
indic
induc
immun
respons
mous
sera
also
test
abil
neutral
merscov
emc
isol
even
singl
immun
adenoviralbas
mer
vaccin
induc
detect
level
merscovneutr
antibodi
anim
test
week
booster
immun
anim
develop
robust
level
neutral
antibodi
control
anim
inocul
ad
fig
mice
immun
highest
neutral
titer
observ
compar
mice
immun
although
signific
differ
group
note
result
might
suggest
express
secret
protein
induc
stronger
respons
led
better
antibodymedi
neutral
activ
compar
fig
gene
encod
solubl
form
design
shown
diagram
posit
rbd
small
dot
transmembran
domain
stripe
indic
divid
two
subdomain
posit
vector
use
gener
recombin
replicationdefici
adenovirus
homolog
recombin
adenovir
genom
dna
b
detect
merss
protein
immunocytochem
stain
cell
infect
moi
use
sera
mice
obtain
three
week
second
boost
neg
control
mock
ad
cell
treat
notabl
one
main
limit
use
adenoviralbas
vaccin
human
would
presenc
antiadenovir
neutral
immun
larg
percentag
camel
popul
thu
demonstr
potenti
propos
use
candid
vaccin
deploy
veterinari
vaccin
dromedari
camel
evalu
presenc
antihuman
adenoviru
type
neutral
antibodi
speci
shown
fig
neutral
detect
sera
dromedari
camel
encourag
first
indic
potenti
candid
vaccin
dromedari
camel
provid
evid
potenti
use
vaccin
dromedari
camel
determin
suscept
dromedari
camel
cell
infect
human
adenoviru
serotyp
human
dromedari
camel
pbmc
cell
transduc
recombin
adenoviru
express
egfp
evalu
flow
cytometri
analysi
egfp
express
shown
fig
human
well
dromedari
camel
pbmc
success
infect
moreov
larg
percentag
dromedari
camel
fibroblast
cell
line
dubca
infect
indic
human
adenoviru
type
inde
effici
infect
camel
cell
fig
f
character
immun
respons
induc
adenovir
vector
vaccin
balbc
mice
immun
intramuscularli
viral
particl
ad
c
respect
boost
intranas
amount
viru
three
week
later
b
antibodi
level
measur
indic
time
point
elisa
static
signific
differ
tukey
test
mark
bar
asterisk
p
p
p
p
c
respect
describ
fig
merscovneutr
titer
vnt
measur
everi
week
primari
immun
use
vero
cell
determin
highest
dilut
inhibit
merscov
infect
fig
presenc
antiadenoviru
type
immun
dromedari
camel
sera
twelv
human
dromedari
camel
sera
test
presenc
antiadenoviru
neutral
antibodi
use
standard
adenovir
neutral
assay
result
show
adenoviralbas
vaccin
express
fulllength
subunit
protein
induc
merscovspecif
neutral
antibodi
respons
mice
import
demonstr
whether
dromedari
camel
vaccin
candid
vaccin
convalesc
merscov
infect
similar
respons
protect
merscov
challeng
sinc
may
indic
whether
vaccineinduc
respons
inde
protect
futur
use
vaccin
veterinari
vaccin
dromedari
camel
would
possibl
previou
studi
shown
rbd
sarscov
present
subunit
strongli
react
antisera
sar
patient
convalesc
phase
deplet
rbdspecif
antibodi
sar
patient
result
signific
elimin
neutral
activ
rbd
main
domain
induc
neutral
antibodi
tcell
immun
respons
sarscov
infect
truncat
rbd
merscov
protein
recent
report
potent
inhibit
viral
infect
induc
strong
neutral
antibodi
respons
sarscov
neither
structur
protein
induc
apoptosi
vero
cell
histopatholog
chang
observ
variou
tissu
rat
immun
recombin
adenoviru
contain
truncat
fragment
sarscov
contrast
vaccin
recombin
modifi
mva
express
sarscov
protein
associ
enhanc
hepat
challeng
sarscov
sarscov
shown
infect
hepatocyt
caus
hepat
human
case
rais
concern
safeti
vaccin
contain
fulllength
sarscov
protein
causal
relationship
induct
hepat
fulllength
natur
protein
could
conclus
demonstr
presum
gene
less
risk
spontan
recombin
wild
type
viru
follow
gener
new
viru
type
thu
believ
merscov
vaccin
would
prefer
vaccin
candid
format
howev
altern
antigen
format
entir
sectodomain
rbd
domain
could
evalu
comparison
sinc
capac
immun
strategi
protect
infect
requir
challeng
test
clinic
relev
merscov
diseas
anim
model
dromedari
camel
establish
model
also
import
exclud
potenti
vaccineinduc
immunopatholog
seen
felin
infecti
periton
viru
model
end
mous
model
merscov
infect
gener
prior
transduct
anim
adenovir
vector
express
human
hostcel
receptor
dipeptidyl
peptidas
recent
report
mous
model
also
consid
futur
evalu
protect
efficaci
adenovirusbas
vaccin
investig
necessari
evalu
mucos
immun
ultim
protect
efficaci
dromedari
camel
proper
anim
model
result
demonstr
recombin
adenovirus
encod
merss
antigen
may
protect
vaccin
candid
safe
profil
moreov
also
investig
present
studi
infect
adenoviru
type
dromedari
camel
cell
presenc
antiadenoviru
type
neutral
antibodi
limit
set
dromedari
camel
sera
altogeth
present
studi
support
explor
vaccin
target
anim
reservoir
reduc
risk
human
exposur
merscov
